Olon S.p.A. is an Italian manufacturer of APIs, with Headquarters and 5 manufacturing facilities located in Italy, and originates from the merger of the previous Solmag and Antibioticos.

In May 2016 Olon S.p.A. acquired INFA Group, including other 3 manufacturing facilities (2 located in Italy and 1 in Spain) and in June 2017 acquired Ricerca Bioscience with a plant in Concord, Ohio, USA. With the merges Olon S.p.A. will improve its products portfolio and strengthen its presence in the global market.

Olon USA Inc.
The wholly owned subsidiary meant to strengthen Olon’s position in the U.S. market.

P&R Shanghai International Trading Co. Ltd
International trading company focused on providing qualified sources and services in the Far East for the Group, as well as developing commercial partnerships for local distribution.


Olon S.p.A.’s Mission is to be a world leader in the manufacturing and sales of advanced intermediates and active pharmaceutical ingredients (APIs) for human's and animal's health.


We have more than a century experience in fermentation and are one of the most important players in the production of High Potency Drugs, as well as cytotoxic substances, with dedicated high containment facilities.
Antineoplastic compounds, immunosuppressive agents, hormones and antibiotics, retinoids, antivirals, psychotropic and controlled substances as well as compounds for CNS, cardiovascular and metabolic diseases complete our wide product portfolio.


Our expertise can be summarized as follows:

  • Development of innovative, original technology platforms for the production of APIs
  • Custom Synthesis
  • Contract Manufacturing
  • Dossiers for Finished Dosage Forms
  • Process Improvement